Indiana University
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Indiana University sits in the top decile of US sponsors by registered trial count (#38 of 15,742 sponsors by registered trial count).
Indiana University: 890 sponsored US clinical trials, 156 recruiting.
Indiana University sponsors 890 registered US clinical trials on ClinicalTrials.gov, 156 of them currently recruiting, and 561 completed. 104 of these trials are in Phase 3-4 (later-stage) and 126 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Alzheimer Disease, with 11 trials.
Top-decile sponsor footprint
Indiana University ranks in the top decile of sponsors by registered trial count (#38 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
561 of 688 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
890 total, page 18 of 18
Assessment of the Pulmonary Diffusion Capacity in Healthy Infants and Infants With Chronic Lung Disease
NCT00428038
Safety and Effectiveness of D-Cycloserine in Children With Autism
NCT00198120
Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.
NCT00550147
Assessment of Airway Obstruction in Infants With Lower Respiratory Infections
NCT00435994
A Study of Sertraline and Early Alprazolam XR Administration Versus Sertraline Only in Panic Disorder Patients
NCT00198094
Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors
NCT00720590
Galantamine Augmentation of Escitalopram for Treatment of Depression
NCT00423969
Hypertension in Hemodialysis
NCT00067665
Serotonin Transporter Genetic Variation and Amygdalar Activation Correlates of Antidepressant Response
NCT00456430
Functional Connectivity in Mood Regulating Circuit In Bipolar Depression and Mania
NCT00457054
Assessment of Changes in Abdominal Fat
NCT00228579
Interventions to Increase HBV Vaccinations in Sexually Transmitted Disease (STD) Clinics
NCT00739752
Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer
NCT00198237
Immunosuppressive Effects of Mycophenolate Mofetil and Valganciclovir in Kidney Transplant Recipients
NCT00198224
A Comparison of Three Different Formulations of Prednisolone Acetate 1%
NCT00345046
A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR
NCT00198159
Prospective Study of Celiac Block Injection: 1 vs. 2
NCT00583479
A Prospective Study of EUS Guided Celiac Block
NCT00583271
Treatment of Children With Obstructive Sleep Apnea and Laryngomalacia: the Role of Laser Supraglottoplasty
NCT00394550
Improving Safety by Basic Computerizing Outpatient Prescribing
NCT01091038
Lung Function and Structure in Healthy Infants and Infants With Recurrent Wheezing
NCT00507676
Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors
NCT00198172
Post-Treatment Effects of Naltrexone
NCT00006449
Research on Individualized Treatment for Alcoholism
NCT00523133
Prevention of Diabetes Progression Trial (PDPT)
NCT00198146
Effect of Tonsillar Pillar Closure on Postoperative Pain and Bleeding Risk After Tonsillectomy
NCT00394849
Venlafaxine for Hot Flashes After Breast Cancer
NCT00198250
Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors
NCT00005796
EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer
NCT00004258
Prospective Study of the Impact of Insulin Pump Therapy in Young Children With Type 1 Diabetes
NCT00727220
Treatment for Post-Stroke Depression
NCT00029172
Perillyl Alcohol Followed by Surgery in Treating Patients With Stage II or Stage III Pancreatic Cancer
NCT00003769
Parkinson's Research: The Organized Genetics Initiative
NCT00086073
Early Diabetes Intervention Program
NCT01470937
ERCP in Idiopathic Recurrent Acute Pancreatitis
NCT01583517
Effects of Comprehensive Care for Knee OA
NCT00000404
Doxycycline and OA Progression
NCT00000403
International SMA Patient Registry
NCT00466349
Psychosocial Treatment for Acute Low Back Pain
NCT00000418
Effects of Strength Training on Knee Osteoarthritis
NCT00000406
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 56 |
| Phase 2 | 70 |
| Phase 3 | 28 |
| Phase 4 | 76 |
Therapeutic Areas
What is open in the Indiana University pipeline
156 recruiting of 890 indexed (18% open); 561 completed (63%).
Phase mix: 104 late (III/IV) vs 126 early (I/II) (balanced across stages).
Top condition: Alzheimer Disease (11 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Indiana University: open-pipeline peers nationwide
Peers matched on 890 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
Indiana University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 890 trials (± recruiting share)
- University of California, Los Angeles · 897 trials · 18% recruiting
- Hoffmann-La Roche · 909 trials · 8% recruiting
- Brigham and Women's Hospital · 937 trials · 15% recruiting
- University of Texas Southwestern Medical Center · 837 trials · 19% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Edwards Lifesciences · 18% recruiting · 57 trials
- University of South Florida · 17% recruiting · 252 trials
- VA Office of Research and Development · 17% recruiting · 1,668 trials
- ConvaTec · 18% recruiting · 17 trials
Related
What to do with this Indiana University page
890 registered trials is a research-attention snapshot, not an endorsement of Indiana University or any single study.
- 156 of Indiana University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Alzheimer Disease is the condition Indiana University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Alzheimer Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Indiana University pipeline card: 890 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.